PATH Stock Analysis: Uipath | NYSE
Software - Infrastructure | NYSE, USA | Market Cap: 6.838m USD | 12M Return: -9.4% | US90364P1057 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 667M
EPS Trend: 39.7%
Qual. Beats: 1
Rev. Trend: 98.6%
Qual. Beats: 6
Warnings
Tailwinds
No distinct edge detected
Seasonality 5.4 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
UiPath, Inc. (NYSE: PATH) provides an enterprise automation platform offering robotic process automation (RPA) solutions across the United States, Romania, the United Kingdom, the Netherlands, and other international markets. The company, founded in 2005 and headquartered in New York, is a mid-cap stock in the GICS Information Technology sector, specifically classified within the Systems Software sub-industry, and went public in April 2021.
Its integrated UiPath platform combines AI agents, software robots, human users, and AI models within coordinated workflows. Core platform components include UiPath Maestro for process orchestration and process intelligence, an agent builder, RPA and API automation, intelligent document extraction and processing, test cloud capabilities for quality assurance, packaged and prebuilt agentic solutions, and centralized governance tools spanning automations, AI agents, and manual tasks.
UiPath serves a diverse customer base across the financial services, healthcare, manufacturing, retail, and public sectors. The RPA and intelligent automation industry has experienced strong growth as organizations seek to streamline repetitive business processes, and vendors like UiPath have increasingly incorporated generative AI and agentic capabilities into their platforms to address more complex, decision-based workflows beyond traditional task automation.
- Revenue growth deceleration pressures valuation multiple
- Microsoft Power Automate competition intensifies in RPA market
- Agentic AI platform expansion drives enterprise deal pipeline
| Net Income: 361.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.12 > 0.02 and ΔFCF/TA 0.54 > 1.0 |
| NWC/Revenue: 65.05% < 20% (prev 86.35%; Δ -21.30% < -1%) |
| CFO/TA 0.13 > 3% & CFO 373.2m > Net Income 361.9m |
| Net Debt (-1.13b) to EBITDA (236.9m): -4.79 < 3 |
| Current Ratio: 2.39 > 1.5 & < 3 |
| Outstanding Shares: last quarter (523.0m) vs 12m ago -3.66% < -2% |
| Gross Margin: 82.50% > 18% (prev 82.86%; Δ -0.36% > 0.5%) |
| Asset Turnover: 62.58% > 50% (prev 57.73%; Δ 4.85% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.39 (Total Current Assets 1.93b - Total Current Liabilities 807.3m) / Total Assets 2.91b |
| B: -0.57 (Retained Earnings -1.65b / Total Assets 2.91b) |
| C: 0.08 (EBIT TTM 210.9m / Avg Total Assets 2.75b) |
| D: 2.03 (Book Value of Equity 1.95b / Total Liabilities 958.8m) |
| Altman-Z'' = 3.33 = A |
| DSRI: 0.69 (Receivables 307.1m/389.1m, Revenue 1.72b/1.50b) |
| GMI: 1.00 (GM 82.86% / 82.50%) |
| AQI: 1.71 (AQ_t 0.30 / AQ_t-1 0.18) |
| SGI: 1.15 (Revenue 1.72b / 1.50b) |
| TATA: -0.00 (NI 361.9m - CFO 373.2m) / TA 2.91b) |
| Beneish M = -2.75 (Cap -4..+1) = A |
As of October 06, 2026, the stock is trading at USD 13.16 with a total of 29,348,958 shares traded. Over the past week, the price has changed by +7.96%, over one month by -6.07%, over three months by +11.24% and over the past year by -9.37%.
Current recommended Stop Loss: 12.20 (which is 7.3% or 1.3 ATR below the current price).
Uipath has received a consensus analysts rating of 3.14. Therefore, it is recommended to hold PATH.
- StrongBuy: 2
- Buy: 1
- Hold: 16
- Sell: 2
- StrongSell: 0
| Analysts Target Price | 15.5 | 17.8% |
P/E Trailing = 19.5821
P/E Forward = 16.7224
P/S = 3.9733
P/B = 3.4877
P/EG = 0.4777
Revenue TTM = 1.72b USD
EBIT TTM = 210.9m USD
EBITDA TTM = 236.9m USD
Long Term Debt = unknown (none)
Short Term Debt = 10.3m USD (from shortTermDebt, last fiscal year)
Debt = 149.2m USD (from shortLongTermDebtTotal, last quarter) + Leases 79.8m
Net Debt = -1.13b USD (calculated: Debt 149.2m - CCE 1.28b)
Enterprise Value = 5.70b USD (6.84b + Debt 149.2m - CCE 1.28b)
Interest Coverage Ratio = unknown (Ebit TTM 210.9m / Interest Expense TTM 0.0)
EV/FCF = 15.71x (Enterprise Value 5.70b / FCF TTM 363.0m)
FCF Yield = 6.36% (FCF TTM 363.0m / Enterprise Value 5.70b)
FCF Margin = 21.09% (FCF TTM 363.0m / Revenue TTM 1.72b)
Net Margin = 21.03% (Net Income TTM 361.9m / Revenue TTM 1.72b)
Gross Margin = 82.50% ((Revenue TTM 1.72b - Cost of Revenue TTM 301.1m) / Revenue TTM)
Gross Margin QoQ = 80.36% (prev 81.13%)
Tobins Q-Ratio = 1.96 (Enterprise Value 5.70b / Total Assets 2.91b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 149.2m)
Taxrate = 31.72% (16.8m / 52.9m)
NOPAT = 144.0m (EBIT 210.9m * (1 - 31.72%))
Current Ratio = 2.39 (Total Current Assets 1.93b / Total Current Liabilities 807.3m)
Debt / Equity = 0.08 (Debt 149.2m / totalStockholderEquity, last quarter 1.95b)
Debt / EBITDA = -4.79 (Net Debt -1.13b / EBITDA 236.9m)
Debt / FCF = -3.13 (Net Debt -1.13b / FCF TTM 363.0m)
Total Stockholder Equity = 1.96b (last 4 quarters mean from totalStockholderEquity)
RoA = 13.16% (Net Income 361.9m / Total Assets 2.91b)
RoE = 18.42% (Net Income TTM 361.9m / Total Stockholder Equity 1.96b)
RoCE = 10.04% (EBIT 210.9m / Capital Employed (Total Assets 2.91b - Current Liab 807.3m))
RoIC = 7.11% (NOPAT 144.0m / Invested Capital 2.02b)
WACC = 10.91% (E(6.84b)/V(6.99b) * Re(11.15%) + D(149.2m)/V(6.99b) * Rd(0.0%) * (1-Tc(0.32)))
Discount Rate = 11.15% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -96.72 | Cagr: -3.75%
[DCF] Terminal Value 70.15% ; FCFF base≈341.6m ; Y1≈391.6m ; Y5≈576.4m
[DCF] Fair Price = 15.55 (EV 5.97b - Net Debt -1.13b = Equity 7.10b / Shares 456.5m; r=10.91% [WACC]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 39.71 | EPS CAGR: 9.40% | SUE: 2.04 | # QB: 1
Revenue Correlation: 98.64 | Revenue CAGR: 11.94% | SUE: 1.52 | # QB: 6
EPS current Quarter (2026-10-31): EPS=0.19 | Chg30d=+2.25% | Revisions=+13% | Analysts=20
EPS current Year (2027-01-31): EPS=0.79 | Chg30d=+0.54% | Revisions=+31% | GrowthEPS=+9.3% | GrowthRev=+11.3%
EPS next Year (2028-01-31): EPS=0.92 | Chg30d=+1.58% | Revisions=+32% | GrowthEPS=+17.0% | GrowthRev=+8.4%
[Analyst] Revisions Ratio: +30% (up=29, down=15)